Medical and behavioral symptoms as potential medication side effects in adults with developmental disabilities

American Journal on Mental Retardation

Volumn 110, Issue 3, 2005, Pages

  Valdovinos, Maria G ^a   Caruso, Mary ^a,b   Roberts, Celeste ^a   Kim, Geunyoung ^a   Kennedy, Craig H ^a  

^a VANDERBILT UNIVERSITY   (United States)

^b UNIVERSITY OF KANSAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; LITHIUM; NEUROLEPTIC AGENT; PROPRANOLOL; PSYCHOTROPIC AGENT;

ANEMIA; APPETITE DISORDER; BEHAVIOR; BEHAVIOR DISORDER; CONSTIPATION; DEFECATION; DEVELOPMENTAL DISORDER; DRUG EFFECT; FEVER; HAIR LOSS; HUMAN; HYPERSALIVATION; HYPERTENSION; INSOMNIA; MEMORY DISORDER; MENTAL HEALTH; MOOD; MOOD DISORDER; MOTOR DYSFUNCTION; NAIL COLOR DEFECT; NAIL DISEASE; NAUSEA AND VOMITING; NOCTURNAL ENURESIS; NOSE CONGESTION; PRESCRIPTION; PRURITUS; RETROSPECTIVE STUDY; REVIEW; RUMINATION; SEIZURE; SIDE EFFECT; SLEEP; SLEEP DISORDER; SPEECH DISORDER; SWEATING; SYMPTOMATOLOGY; THIRST; URINARY DYSFUNCTION; WALKING; WEIGHT GAIN; XEROSTOMIA;

ADULT; AGED; FEMALE; HEALTH STATUS; HUMANS; MALE; MENTAL RETARDATION; MIDDLE AGED; PSYCHOTROPIC DRUGS; RETROSPECTIVE STUDIES;

EID: 17644378396     PISSN: 08958017     EISSN: None     Source Type: Journal    
DOI: 10.1352/0895-8017(2005)110<164:MABSAP>2.0.CO;2     Document Type: Review

References (25)

1. Advokat, C. D., Mayville, E. A., & Matson, J. L. (2000). Side effect profiles of atypical antipsychotics, typical antipsychotics, or no psychotropic medications in persons with mental retardation. Research in Developmental Disabilities, 21, 75-84.
2. Barron, J., & Sandman, C. A. (1983). Relationship of sedative-hypnotic response to self-injurious behavior and stereotypy by mentally retarded clients. American Journal of Mental Deficiency, 88, 177-186.
3. Bodfish, J. W., Newell, K. M., Sprague, R. L., Harper, V. N., & Lewis, M. H. (1997). Akathisia in adults with mental retardation: Development of the Akathisia Ratings Movement Scale (ARMS). American Journal on Mental Retardation, 101, 413-423.
4. Brasic, J. R., Young, J. G., Furman, J., Conte, R. M., Baisley, W. E., & Jaslow, R. I. (1997). Psychoactive Medication Quality Assurance Rating Survey (PQRS). Journal of Developmental and Physical Disabilities, 9, 311-336.
5. Campbell, M., & Palij, M. (1985). Measurement of side effects including tardive dyskinesia. Psychopharmacology Bulletin, 21, 1063-1080.
6. Chadsey-Rusch, J., & Sprague, R. L. (1989). Maladaptive behaviors associated with neuroleptic drug maintenance. American Journal on Mental Retardation, 93, 607-617.
7. Christian, L., Snycerski, S. M., Singh, N. N., & Poling, A. (1999). Direct service staff and their perceptions of psychotropic medication in non-institutional settings for people with intellectual disability. Journal of Intellectual Disability Research, 43, 88-93.
8. Edwards, I. R., & Biriell, C. (1994). Harmonisation in pharmacovigilance. Drug Safety, 10, 93-101.
9. Harbord, M. G. (2000). Significant anticonvulsant side-effects in children and adolescents. Journal of Clinical Neuroscience, 7, 213-216.
10. Kalachnik, J. E. (1988). Medication monitoring procedures: Thou shall, here's how. In K. D. Gadow & A. D. Poling (Eds.), Pharmacotherapy and mental retardation (pp. 231-268). Boston: College-Hill.
11. Kalachnik, J. E. (1999). "You tell me it's the institution, well, you know, you better free your mind instead." In N. A. Wieseler & R. H. Hanson (Eds.), Challenging behavior of persons with mental health disorders and severe developmental disabilities (pp. 151-203). Washington, DC: American Association on Mental Retardation.
12. Karch, F. E., Smith, C. L., Kerzner, B., Mazzullo, J. M., Weintraub, M., & Lasagna, L. (1976). Commentary: Adverse drug reactions - A matter of opinion. Clinical Pharmacology and Therapeutics, 19, 489-492.
13. Kastner, T., Walsh, K. K., & Fraser, M. (2001). Undiagnosed medical conditions and medication side effects presenting as behavioral/psychiatric problems in people with mental retardation. Mental Health Aspects of Developmental Disabilities, 4, 101-107.
14. Kennedy, C. H., & Meyer, K. A. (1998). The use of psychotropic medication for people with severe disabilities and challenging behavior: Current status and future directions. Journal of the Association for Persons with Severe Handicaps, 23, 83-97.
15. Kennedy, C. H., & Thompson, T. (2000). Health conditions contributing to problem behavior among people with mental retardation and developmental disabilities. In M. L. Wehmeyer & J. R. Patton (Eds.), Mental retardation in the 21st century (pp. 211-231). Austin, TX: ProEd.
16. Matson, J. L., Mayville, E. A., Bielecki, J., Barnes, W. H., Bamburg, J. W., & Baglio, C. S. (1998). Reliability of the Matson Evaluation of Drug Side Effects Scale (MEDS). Research in Developmental Disabilities, 19, 501-506.
17. McKee, J. R. (1996). Adverse medication event history clarification: A multidisciplinary approach. The Consultant Pharmacist, 11, 938-942.
18. Medical Economics Company. (2001). Physicians desk reference. Oradell, NJ: Author.
19. Naranjo, C. A., Busto, U., Sellers, E. M., Sandor, P., Ruiz, I., Roberts, E. A., Janecek, E., Donecq, C., & Greenblatt, D. J. (1981). A method for estimating the probability of adverse drug reactions. Clinical Pharmacological Therapy, 30, 239-245.
20. Naranjo, C. A., Shear, N. H., & Lanctôt, K. L. (1992). Advances in the diagnosis of adverse drug reactions. Journal of Clinical Pharmacology, 32, 897-904.
21. National Institute of Mental Health. (1985). AIMS (Abnormal Involuntary Movement Scale). Psychopharmacology Bulletin, 21, 1077-1079.
22. Rabkin, J. G., Markowitz, J. S., Ocepek-Welikson, K., & Wager, S. S. (1992). General versus systematic inquiry about emergent clinical events with SAFTEE: Implications for clinical research. Journal of Clinical Psychopharmacology, 12, 3-10.
23. Sprague, R. L., Kalachnik, J. E., & Slaw, K. M. (1989). Psychometric properties of the Dyskinesia Identification System: Condensed User Scale (DISCUS). Mental Retardation, 27, 141-148.
24. Valdovinos, M. G., & Schroeder, S. R. (2003). The effects of a computerized monitoring system of psychotropic medication use by people with developmental disabilities on staff reported side effects. Journal of Developmental and Physical Disabilities, 15, 299-334.
25. Valdovinos, M. G., Schroeder, S. R., & Kim, G. (2003). Prevalence and correlates of psychotropic medication use among adults with developmental disabilities: 1970-2000. International Review of Research in Mental Retardation, 26, 175-220.